SNAI1 Antibody (YA5064)

Cat. No.: HY-P85372: Data Sheet User Guide for Antibodies
FAQs
Technical Support

SNAI1 Antibody (YA5064) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SNAI1.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

사이즈		재고
50 μL		견적 받기
100 μL		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
제품 설명

제품 설명

SNAI1 Antibody (YA5064) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SNAI1.

Host

Mouse

Clonality

Monoclonal

분자량

Predicted band size: 29 kDa;

Species Reactivity

Human

SwissProt ID

O95863

Gene ID

6615 [NCBI]

Immunogen

Recombinant human SNAI1. The exact sequence is proprietary to MCE.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-2000

Sensitivity	Endogenous	Purity	affinity purified by Protein G
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

선적

Shipping with blue ice.

Background

Function：Involved in induction of the epithelial to mesenchymal transition (EMT), formation and maintenance of embryonic mesoderm, growth arrest, survival and cell migration (PubMed:10655587, PubMed:15647282, PubMed:20389281, PubMed:20562920, PubMed:21952048, PubMed:25827072). Binds to 3 E-boxes of the E-cadherin/CDH1 gene promoter and to the promoters of CLDN7 and KRT8 and, in association with histone demethylase KDM1A which it recruits to the promoters, causes a decrease in dimethylated H3K4 levels and represses transcription (PubMed:10655587, PubMed:20389281, PubMed:20562920). The N-terminal SNAG domain competes with histone H3 for the same binding site on the histone demethylase complex formed by KDM1A and RCOR1, and thereby inhibits demethylation of histone H3 at 'Lys-4' (in vitro) (PubMed:20389281, PubMed:21300290, PubMed:23721412). During EMT, involved with LOXL2 in negatively regulating pericentromeric heterochromatin transcription (PubMed:16096638). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (By similarity). Associates with EGR1 and SP1 to mediate tetradecanoyl phorbol acetate (TPA)-induced up-regulation of CDKN2B, possibly by binding to the CDKN2B promoter region 5'-TCACA-3 (PubMed:20121949). In addition, may also activate the CDKN2B promoter by itself (PubMed:20121949)

Subcellular Localization：Nucleus; Cytoplasm

Expression：
Tissue_specificity:It is expressed in a variety of tissues, with the highest expression in the kidney. It is also expressed in both mesenchymal cells and epithelial cell lines.

Induction:Induced by TPA maximally by 2.5-fold at 4 hours, in HepG2 cells (at protein level)

Subunit：Interacts (via SNAG domain) with WTIP (via LIM domains) (By similarity). Interacts (via SNAG domain) with LIMD1 (via LIM domains), and AJUBA (via LIM domains) (PubMed:18331720). Interacts with LOXL2 and LOXL3 (PubMed:16096638).

Synonyms

SNAI1; SNAH; Zinc finger protein SNAI1; Protein snail homolog 1; Protein sna

각종 서류

User Guide for Antibodies (1077 KB)